Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis

Amyloid. 2019;26(sup1):113-114. doi: 10.1080/13506129.2019.1583200.

Authors

Suzanne Lentzsch¹, Galina G Lagos¹, Raymond L Comenzo², Jeffrey A Zonder³, Silva Pregja³, Keren Osman⁴, Wei-Yann Tsai¹, Heather Landau⁵, Vaishali Sanchorawala⁶

Affiliations

¹ a Columbia University Medical Center , New York , NY , USA.
² b Tufts Medical Center , Boston , MA , USA.
³ c Karmanos Cancer Institute , Detroit , MI , USA.
⁴ d Mt. Sinai School of Medicine , New York , NY , USA.
⁵ e Memorial Sloan Kettering Cancer Center , New York , NY , USA.
⁶ f Boston Medical Center , Boston , MA , USA.

PMID: 31343313
DOI: 10.1080/13506129.2019.1583200

No abstract available

Publication types

Clinical Trial, Phase II
Multicenter Study

MeSH terms

Adult
Aged
Bendamustine Hydrochloride / administration & dosage*
Bendamustine Hydrochloride / adverse effects
Dexamethasone / administration & dosage*
Dexamethasone / adverse effects
Disease-Free Survival
Female
Follow-Up Studies
Humans
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Immunoglobulin Light-chain Amyloidosis / mortality*
Male
Middle Aged
Recurrence
Survival Rate

Substances

Dexamethasone
Bendamustine Hydrochloride